

Date of preparation: 2022-01-18

Abbreviated name of the Issuer: MABION S.A.

Subject matter: Mabion receives an additional order to provide analytical product quality control services under the manufacturing agreement with Novavax, Inc.

Legal basis: Article 17 (1) of MAR – confidential information

Content of the Report:

With reference to Current Report no. 52/2021 of 8 October 2021 regarding the conclusion of a commercial contractual production agreement (“Manufacturing Agreement”) with Novavax, Inc. (“Novavax”), the Management Board of Mabion S.A. (“Company”) hereby informs that on 18 January 2022, under the Manufacturing Agreement, the parties signed an additional order in the form of Statement of Work #2 (“SOW#2”), pursuant to which the Company will provide analytical services to Novavax with respect to analytical testing related to quality control of the Nuvaxovid vaccine (“Product”).

Under SOW#2, the Company will in the first place conduct and appropriately document feasibility studies for specific analytical methods not covered by previous contracts or orders and transfer the methods in accordance with Novavax's specifications. The above work will commence already in January 2022 and will be completed, in line with the expectations of both parties, not later than the third quarter of 2022. Subsequently, during the term of the Manufacturing Agreement, i.e. in the years 2022-2025, the Company will employ the above-mentioned analytical methods to perform tests indicated by Novavax on samples of the Product, whereas, pursuant to SOW#2, the tests may cover samples originating from the Company's facility as well as samples possibly supplied by Novavax from other facilities performing contract manufacturing for Novavax.

The value of SOW#2 is dependent on the number of analytical tests conducted by the Company in different years, but based on the Company's current estimates, despite the fact that the contract involves high margins, the financial value in relation to the originally signed Manufacturing Agreement should not be material when assessing the significance of the additional order for the Company. However, the extension of cooperation with Novavax to another new area, i.e. delivery of additional contract analytics in the key area, i.e. related to the release of individual batches of the Product onto the market, remains a very important business factor for the Company.

The selection of the Company in the tender procedure carried out by the contractor once again confirms the Company's credentials as a Contract Development and Manufacturing Organization (CDMO).